NCCN guidelines® Insights: Non-small cell lung cancer, version 4.2016 Featured updates to the NCCN guidelines

David S. Ettinger, Douglas E. Wood, Wallace Akerley, Lyudmila A. Bazhenova, Hossein Borghaei, David Ross Camidge, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D'Amico, Thomas J. Dilling, M. Chris Dobelbower, Ramaswamy Govindan, Mark Hennon, Leora Horn, Thierry M. Jahan, Ritsuko Komaki, Rudy P Lackner, Michael Lanuti, Rogerio Lilenbaum, Jules LinBilly W. Loo, Renato Martins, Gregory A. Otterson, Jyoti D. Patel, Katherine M. Pisters, Karen Reckamp, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, Neelesh Sharma, James Stevenson, Scott J. Swanson, Kurt Tauer, Stephen C. Yang, Kristina Gregory, Miranda Hughes

Research output: Contribution to journalReview article

219 Citations (Scopus)

Abstract

These NCCN Guidelines Insights focus on recent updates in the 2016 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC; Versions 1-4). These NCCN Guidelines Insights will discuss new immunotherapeutic agents, such as nivolumab and pembrolizumab, for patients with metastatic NSCLC. For the 2016 update, the NCCN panel recommends immune checkpoint inhibitors as preferred agents (in the absence of contraindications) for second-line and beyond (subsequent) therapy in patients with metastatic NSCLC (both squamous and nonsquamous histologies). Nivolumab and pembrolizumab are preferred based on improved overall survival rates, higher response rates, longer duration of response, and fewer adverse events when compared with docetaxel therapy.

Original languageEnglish (US)
Pages (from-to)255-264
Number of pages10
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume14
Issue number3
DOIs
StatePublished - Mar 1 2016

Fingerprint

Non-Small Cell Lung Carcinoma
docetaxel
Guidelines
Histology
Survival Rate
Therapeutics
nivolumab
pembrolizumab

ASJC Scopus subject areas

  • Oncology

Cite this

NCCN guidelines® Insights : Non-small cell lung cancer, version 4.2016 Featured updates to the NCCN guidelines. / Ettinger, David S.; Wood, Douglas E.; Akerley, Wallace; Bazhenova, Lyudmila A.; Borghaei, Hossein; Camidge, David Ross; Cheney, Richard T.; Chirieac, Lucian R.; D'Amico, Thomas A.; Dilling, Thomas J.; Chris Dobelbower, M.; Govindan, Ramaswamy; Hennon, Mark; Horn, Leora; Jahan, Thierry M.; Komaki, Ritsuko; Lackner, Rudy P; Lanuti, Michael; Lilenbaum, Rogerio; Lin, Jules; Loo, Billy W.; Martins, Renato; Otterson, Gregory A.; Patel, Jyoti D.; Pisters, Katherine M.; Reckamp, Karen; Riely, Gregory J.; Schild, Steven E.; Shapiro, Theresa A.; Sharma, Neelesh; Stevenson, James; Swanson, Scott J.; Tauer, Kurt; Yang, Stephen C.; Gregory, Kristina; Hughes, Miranda.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 14, No. 3, 01.03.2016, p. 255-264.

Research output: Contribution to journalReview article

Ettinger, DS, Wood, DE, Akerley, W, Bazhenova, LA, Borghaei, H, Camidge, DR, Cheney, RT, Chirieac, LR, D'Amico, TA, Dilling, TJ, Chris Dobelbower, M, Govindan, R, Hennon, M, Horn, L, Jahan, TM, Komaki, R, Lackner, RP, Lanuti, M, Lilenbaum, R, Lin, J, Loo, BW, Martins, R, Otterson, GA, Patel, JD, Pisters, KM, Reckamp, K, Riely, GJ, Schild, SE, Shapiro, TA, Sharma, N, Stevenson, J, Swanson, SJ, Tauer, K, Yang, SC, Gregory, K & Hughes, M 2016, 'NCCN guidelines® Insights: Non-small cell lung cancer, version 4.2016 Featured updates to the NCCN guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 14, no. 3, pp. 255-264. https://doi.org/10.6004/jnccn.2016.0031
Ettinger, David S. ; Wood, Douglas E. ; Akerley, Wallace ; Bazhenova, Lyudmila A. ; Borghaei, Hossein ; Camidge, David Ross ; Cheney, Richard T. ; Chirieac, Lucian R. ; D'Amico, Thomas A. ; Dilling, Thomas J. ; Chris Dobelbower, M. ; Govindan, Ramaswamy ; Hennon, Mark ; Horn, Leora ; Jahan, Thierry M. ; Komaki, Ritsuko ; Lackner, Rudy P ; Lanuti, Michael ; Lilenbaum, Rogerio ; Lin, Jules ; Loo, Billy W. ; Martins, Renato ; Otterson, Gregory A. ; Patel, Jyoti D. ; Pisters, Katherine M. ; Reckamp, Karen ; Riely, Gregory J. ; Schild, Steven E. ; Shapiro, Theresa A. ; Sharma, Neelesh ; Stevenson, James ; Swanson, Scott J. ; Tauer, Kurt ; Yang, Stephen C. ; Gregory, Kristina ; Hughes, Miranda. / NCCN guidelines® Insights : Non-small cell lung cancer, version 4.2016 Featured updates to the NCCN guidelines. In: JNCCN Journal of the National Comprehensive Cancer Network. 2016 ; Vol. 14, No. 3. pp. 255-264.
@article{11e8153460a0427c9c02cdf81d5d304d,
title = "NCCN guidelines{\circledR} Insights: Non-small cell lung cancer, version 4.2016 Featured updates to the NCCN guidelines",
abstract = "These NCCN Guidelines Insights focus on recent updates in the 2016 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC; Versions 1-4). These NCCN Guidelines Insights will discuss new immunotherapeutic agents, such as nivolumab and pembrolizumab, for patients with metastatic NSCLC. For the 2016 update, the NCCN panel recommends immune checkpoint inhibitors as preferred agents (in the absence of contraindications) for second-line and beyond (subsequent) therapy in patients with metastatic NSCLC (both squamous and nonsquamous histologies). Nivolumab and pembrolizumab are preferred based on improved overall survival rates, higher response rates, longer duration of response, and fewer adverse events when compared with docetaxel therapy.",
author = "Ettinger, {David S.} and Wood, {Douglas E.} and Wallace Akerley and Bazhenova, {Lyudmila A.} and Hossein Borghaei and Camidge, {David Ross} and Cheney, {Richard T.} and Chirieac, {Lucian R.} and D'Amico, {Thomas A.} and Dilling, {Thomas J.} and {Chris Dobelbower}, M. and Ramaswamy Govindan and Mark Hennon and Leora Horn and Jahan, {Thierry M.} and Ritsuko Komaki and Lackner, {Rudy P} and Michael Lanuti and Rogerio Lilenbaum and Jules Lin and Loo, {Billy W.} and Renato Martins and Otterson, {Gregory A.} and Patel, {Jyoti D.} and Pisters, {Katherine M.} and Karen Reckamp and Riely, {Gregory J.} and Schild, {Steven E.} and Shapiro, {Theresa A.} and Neelesh Sharma and James Stevenson and Swanson, {Scott J.} and Kurt Tauer and Yang, {Stephen C.} and Kristina Gregory and Miranda Hughes",
year = "2016",
month = "3",
day = "1",
doi = "10.6004/jnccn.2016.0031",
language = "English (US)",
volume = "14",
pages = "255--264",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "3",

}

TY - JOUR

T1 - NCCN guidelines® Insights

T2 - Non-small cell lung cancer, version 4.2016 Featured updates to the NCCN guidelines

AU - Ettinger, David S.

AU - Wood, Douglas E.

AU - Akerley, Wallace

AU - Bazhenova, Lyudmila A.

AU - Borghaei, Hossein

AU - Camidge, David Ross

AU - Cheney, Richard T.

AU - Chirieac, Lucian R.

AU - D'Amico, Thomas A.

AU - Dilling, Thomas J.

AU - Chris Dobelbower, M.

AU - Govindan, Ramaswamy

AU - Hennon, Mark

AU - Horn, Leora

AU - Jahan, Thierry M.

AU - Komaki, Ritsuko

AU - Lackner, Rudy P

AU - Lanuti, Michael

AU - Lilenbaum, Rogerio

AU - Lin, Jules

AU - Loo, Billy W.

AU - Martins, Renato

AU - Otterson, Gregory A.

AU - Patel, Jyoti D.

AU - Pisters, Katherine M.

AU - Reckamp, Karen

AU - Riely, Gregory J.

AU - Schild, Steven E.

AU - Shapiro, Theresa A.

AU - Sharma, Neelesh

AU - Stevenson, James

AU - Swanson, Scott J.

AU - Tauer, Kurt

AU - Yang, Stephen C.

AU - Gregory, Kristina

AU - Hughes, Miranda

PY - 2016/3/1

Y1 - 2016/3/1

N2 - These NCCN Guidelines Insights focus on recent updates in the 2016 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC; Versions 1-4). These NCCN Guidelines Insights will discuss new immunotherapeutic agents, such as nivolumab and pembrolizumab, for patients with metastatic NSCLC. For the 2016 update, the NCCN panel recommends immune checkpoint inhibitors as preferred agents (in the absence of contraindications) for second-line and beyond (subsequent) therapy in patients with metastatic NSCLC (both squamous and nonsquamous histologies). Nivolumab and pembrolizumab are preferred based on improved overall survival rates, higher response rates, longer duration of response, and fewer adverse events when compared with docetaxel therapy.

AB - These NCCN Guidelines Insights focus on recent updates in the 2016 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC; Versions 1-4). These NCCN Guidelines Insights will discuss new immunotherapeutic agents, such as nivolumab and pembrolizumab, for patients with metastatic NSCLC. For the 2016 update, the NCCN panel recommends immune checkpoint inhibitors as preferred agents (in the absence of contraindications) for second-line and beyond (subsequent) therapy in patients with metastatic NSCLC (both squamous and nonsquamous histologies). Nivolumab and pembrolizumab are preferred based on improved overall survival rates, higher response rates, longer duration of response, and fewer adverse events when compared with docetaxel therapy.

UR - http://www.scopus.com/inward/record.url?scp=84961575658&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961575658&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2016.0031

DO - 10.6004/jnccn.2016.0031

M3 - Review article

C2 - 26957612

AN - SCOPUS:84961575658

VL - 14

SP - 255

EP - 264

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 3

ER -